Journal of Medicinal Chemistry · 2003 · 10 citations · 21 references
MedicineNeuroscienceRadiologyDiagnostic ImagingDiagnostic RadiologyMolecular ImagingBrain ImagingNeurodegenerative Disease ImagingNeurotransmissionParkinsonian DisordersRadiopharmaceutical DesignTargeted Imaging AgentsDensityDopamine TransportersNeuroimaging In Parkinson's DiseaseParkinson Disease ImagingTechnetium-99m ChemistryTechnetium-99m LabelingTechnetium-99m Pertechnetate ImagingTechnetium-99m Radiopharmaceuticals
The dopamine transporter (DAT), located presynaptically on dopamine neurons, provides a marker for Parkinson's disease (Pd) and attention deficit hyperactivity disorder (ADHD). In ADHD, DAT density levels are elevated, while in Pd these levels are depleted. The depletion of DAT levels also corresponds with the loss of dopamine. We now describe the design, synthesis, biology, and SPECT imaging in nonhuman primates of second-generation (99m)technetium-based tropane ligands that bind potently and selectively to the DAT. We demonstrate that improved selectivity and biological stability allows sufficient agent to enter the brain and label the DAT in vivo to provide a quantitative measure of DAT density in nonhuman primates. We introduce FLUORATEC (N-[(2-((3'-N'-propyl-(1"R)-3"alpha-(4-fluorophenyl)tropane-2"beta-1-propanoyl)(2-mercaptoethyl)amino)acetyl)-2-aminoethanethiolato]technetium(V) oxide), a DAT imaging agent that has emerged from these studies and is now in phase 1 clinical trials in the U.S.
21
John L. Neumeyer, Alexander Campbell, Shaoyin Wang et al. · Journal of Medicinal Chemistry · 1994 · 164 citations · Full text
Medicine, Chemistry, Pharmacology +11
Peter C. Meltzer, A. Y. Liang, A.-L. Brownell et al. · Journal of Medicinal Chemistry · 1993 · 138 citations · Full text